Business Context and Reporting Period
This Form 6-K is filed by Prana Biotechnology Limited, a foreign private issuer based in South Melbourne, Australia. The report covers the month of May 2008 and was signed on May 28, 2008, by Geoffrey Kempler, Executive Chairman.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notice of a specific corporate event rather than a financial statement.
Material Changes
- Shareholder Interest Change: The registrant reports a "Notice of Change of Substantial Interests to Shareholder (Baywick)." Specific details regarding the magnitude of the change or the nature of the transaction are not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the notification of the shareholder interest change.
Key Facts for Investor Verification
- Verify the specific details of the change in substantial interest held by the shareholder "Baywick."
- Confirm the current shareholding percentage of Baywick following this change.
- Note that the registrant is Prana Biotechnology Limited, not Altery Therapeutics Ltd as indicated in the request metadata.